Sven Rohmann
Acting Chief Executive Officer (also Member of the Board)

Born: 1962
Share holdings: –

Sven Rohmann has been the CEO of the two German biotech companies, BioVisioN and Ganymed Pharmaceuticals. He has also held senior managerial positions within Novartis and Merck-Serono. He spent 10 years at Merck-Serono, which provided him with a strong foothold in the pharmaceutical industry. His career exposed him to pre-clinical, clinical development as well as marketing, business and corporate development. During his tenure at Merck-Serono he headed the establishment of Merck Oncology. Moreover, he has been the Chairman of the Board in Helix BioPharma Corp and ImVisioN and Chief Medical Officer (CMO) of two companies in Austria and USA.

Dr. Rohmann’s unique combination of scientific, pharma, biotech and venture knowledge, an extensive network of contacts among health care providers and research administrators, a thorough knowledge of global research & development as well as EMA/FDA regulatory policies, and a significant experience in M&A and partnering, makes him one of the leading experts in innovation management, value building & capturing.

Anette Sjödin
Chief Business Officer and deputy CEO

Born: 1964
Share holdings: –

Anette Sjödin possesses more than 25 years of experience in the Life Science sector. She is a biochemist with many years of global experience including senior positions in marketing, project management and business development. Her most recent position was in business development at Nestlé Skin Health where she has worked internationally with in- and out licensing and was responsible for strategic alliances.

Joakim Lindén
Acting Chief Financial Officer

Born: 1964
Share holdings: –

Joakim Lindén has a Master of Science in Business and Economics and has been working in Oasmia since 26 March 2019.

Joakim runs his own consulting business and has more than 25 years of experience of change implementation in public and private limited companies in many industries, countries and roles, including as CFO.

Mikael Asp
Chief Technical Officer

Born: 1962
Share holdings: 8,020 shares personally

Mikael has a Master of Science in Chemical Engineering and has 30 years of experience from several companies within the international pharmaceutical industry in research and development, production, quality assurance and as Qualified Person (QP).

Nina Heldring
Acting Chief Medical Officer

Born: 1968
Share holdings: –

Nina Heldring, PhD, has 20 years of experience with pre-clinical and clinical medical research from renowned academic institutes and the pharmaceutical industry. She has a Masters degree in biomedicine and a PhD in medical science from the Karolinska Institute, Stockholm. She previously served as Head of Clinical Development at Oasmia.